MRK · 8-K · 20260804PR090045

Competition and Pricing Pressure

Merck & Co., Inc. · 2026-08-04 · Importance 40 · Surprise 56

JANUVIA/JANUMET sales declined 31% to $429 million because of lower U.S. demand and net pricing amid competition, along with lower demand in China and most other international markets from ongoing generic competition. VAXNEUVANCE sales fell 35% to $148 million, reflecting lower current-period demand in the United States and most international markets due to competitive pressure. ProQuad, M-M-R II and VARIVAX sales decreased 3% to $592 million, primarily because of lower U.S. demand, partly offset by higher U.S. net pricing and stronger European demand. The results indicate significant competitive pressure in diabetes and pneumococcal vaccines, while selected vaccine pricing partially mitigated volume weakness.